Page last updated: 2024-08-22

nsc 3852 and Acute Myelogenous Leukemia

nsc 3852 has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bartels, M; Coffer, PJ; Egan, DA; Govers, AMAP; Lelieveld, D; Sonneveld, E; Wiggers, CRM; Zwaan, CM1

Other Studies

1 other study(ies) available for nsc 3852 and Acute Myelogenous Leukemia

ArticleYear
Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:8

    Topics: Apoptosis; Cell Proliferation; Child; Down Syndrome; Drug Screening Assays, Antitumor; Epigenesis, Genetic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyquinolines; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukemoid Reaction; Nitroso Compounds; Prognosis; Tumor Cells, Cultured

2019